Jeffrey A. Rona - 02 Jun 2021 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Chief Business Officer
Signature
/s/ Danielle Mann by PoA for Jeffrey Rona
Issuer symbol
OVID
Transactions as of
02 Jun 2021
Net transactions value
$0
Form type
4
Filing time
10 Jun 2021, 19:49:07 UTC
Next filing
04 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 02 Jun 2021 Common Stock 100,000 $4.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on June 2, 2022 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.